|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,702.00 GBX | +1.68% |
|
+1.08% | -7.89% |
| 08:52am | What Bundibugyo Ebola vaccines and treatments are under development | RE |
| 07:40am | Royalty Pharma Acquires Royalty Interest in AstraZeneca's Cliramitug | MT |
| Market Cap | 259B 227B 211B 194B 365B 25,012B 370B 2,512B 983B 12,239B 973B 952B 42,278B | P/E 2026 * |
20.9x | P/E 2027 * | 18.3x |
|---|---|---|---|---|---|
| Enterprise Value | 278B 244B 226B 208B 392B 26,864B 398B 2,698B 1,056B 13,145B 1,045B 1,023B 45,409B | EV / Sales 2026 * |
4.4x | EV / Sales 2027 * | 4.06x |
| Free-Float |
96.63% | Yield 2026 * |
2% | Yield 2027 * | 2.11% |
Last Transcript: AstraZeneca PLC
| 1 day | +1.71% | ||
| 1 week | +1.08% | ||
| Current month | -9.91% | ||
| 1 month | -4.42% | ||
| 3 months | -12.62% | ||
| 6 months | -6.33% | ||
| Current year | -7.89% |
| 1 week | 10,524 |  | 12,776 |
| 1 month | 10,524 | | 14,686 |
| Current year | 10,524 | | 15,732 |
| 1 year | 10,466 | | 15,732 |
| 3 years | 9,461 | | 15,732 |
| 5 years | 8,029 | | 15,732 |
| 10 years | 3,996 | | 15,732 |
| Manager | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 66 | 2012-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 52 | 2021-07-31 |
Jeffrey Pott
CMP | Compliance Officer | - | 2022-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 1999-04-05 | |
Pascal Soriot
BRD | Director/Board Member | 66 | 2012-09-30 |
Philip Broadley
BRD | Director/Board Member | 65 | 2017-04-26 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/6/26 | Free | See Remarks | 2 | 0.0000% | ||
| 6/8/26 | Free | See Remarks | 1 | 0.0000% | ||
| 5/20/26 | Sell | See Remarks | -11,893 | 0.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.68% | +1.08% | +22.70% | +17.83% | 259B | |
| -0.93% | +0.64% | +49.92% | +153.43% | 1,048B | |
| +1.94% | +3.54% | +52.31% | +49.51% | 603B | |
| -0.32% | +4.71% | +36.61% | +78.52% | 452B | |
| -0.42% | +0.67% | +30.81% | +21.54% | 327B | |
| -0.16% | +2.74% | +36.02% | +38.04% | 283B | |
| -1.40% | -3.34% | -24.63% | -41.91% | 219B | |
| +0.35% | +2.65% | +20.32% | +56.24% | 198B | |
| +0.86% | -0.25% | +19.24% | +69.16% | 162B | |
| -0.02% | +0.58% | -0.70% | -33.44% | 142B | |
| Average | +0.17% | +1.85% | +24.26% | +40.89% | 369.38B | |
| Weighted average by Cap. | +0.07% | +1.73% | +34.72% | +69.59% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 63.21B 55.39B 51.42B 47.25B 89.03B 6,100B 90.34B 613B 240B 2,985B 237B 232B 10,310B | 66.79B 58.52B 54.33B 49.92B 94.07B 6,445B 95.45B 647B 253B 3,153B 251B 245B 10,894B |
| Net income | 12.43B 10.89B 10.11B 9.29B 17.51B 1,200B 17.77B 120B 47.15B 587B 46.67B 45.66B 2,028B | 13.94B 12.21B 11.34B 10.42B 19.63B 1,345B 19.92B 135B 52.86B 658B 52.32B 51.19B 2,273B |
| Net Debt | 19.2B 16.82B 15.61B 14.35B 27.04B 1,852B 27.43B 186B 72.8B 906B 72.06B 70.5B 3,131B | 11.9B 10.43B 9.68B 8.9B 16.76B 1,149B 17.01B 115B 45.14B 562B 44.68B 43.72B 1,941B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-22 | GBX 12,702.00 | +1.68% | 2,191,992 |
| 26-07-21 | GBX 12,492.00 | +0.90% | 1,829,671 |
| 26-07-20 | GBX 12,380.00 | -1.70% | 1,718,968 |
| 26-07-17 | GBX 12,594.00 | -0.27% | 2,012,949 |
| 26-07-16 | GBX 12,628.00 | +0.49% | 1,602,666 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- AZN Stock
Select your edition
All financial news and data tailored to specific country editions
